Abstract
Based on observations suggesting a role for the tumor suppressor protein p53 in regulating expression of the 67-kDa laminin receptor precursor, 37LRP, we analysed the 37LRP promoter activity in a wild-type p53 (wt p53) ovarian carcinoma cell line and in a cisplatin-resistant subline with mutated p53. We observed an increased promoter activity in wt p53 cells as compared to the mutated-p53 line when the first intron of the 37LRP gene was present in the reporter construct. Cotransfection experiments showed that the promoter is downregulated by both wt and mutated p53. Deletion analysis of the first intron localized an enhancer activity in the first 5′ 214 bp that upregulates both 37LRP and SV40 promoter activity and is repressed by both wt and mutant p53. Cotransfection, mutagenesis and gel-shift experiments identified a functional AP-2 cis-acting element in this intron region that is repressed by increased levels of both wt and mutated p53. Coimmunoprecipitation studies revealed AP-2 in physical association in vivo with both wt and mutated p53, indicating for the first time that interaction of p53 with AP-2 is involved in the repression mechanism and in the regulation of genes involved in cancer growth and progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agoff SN, Hou J, Linzer DIH, Wu B . 1993 Science 259: 84–87
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K . 1987 Current Protocols in Molecular Biology. John Wiley & Sons (ed) New York: Green Publishing Associated and Wiley-Interscience pp 2.1.1–2.1.2
Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B . 1990 Science 249: 912–915
Bates NP, Hurst HC . 1997 Oncogene 15: 473–481
Borellini F, Glazer RI . 1993 J. Biol. Chem. 268: 7923–7928
Butò S, Tagliabue E, Aiello P, Ardini E, Magnifico A, Montuori N, Sobel ME, Colnaghi MI, Ménard S . 1997 Int. J. Biol. Markers 12: 1–5
Butò S, Tagliabue E, Ardini E, Magnifico A, Ghirelli C, van den Brûle F, Castronovo V, Colnaghi MI, Sobel ME, Ménard S . 1998 J. Cell Biochem. 69: 244–251
Castronovo V, Sobel ME . 1990 Biochem. Biophys. Res. Commun. 68: 1110–1117
Clausse N, Van den Brule F, Delvenne P, Jacobs N, Franzen-Detrooz E, Jackers P, Castronovo V . 1998 Biochem. Biophys. Res. Commun. 251: 564–569
Di Leo A, Bajetta E, Biganzoli L, Bohm S, Fabbiani M, Gebbia V, Lupi G, Mariani L, Ménard S, Oriana S, Ottone F, Pilotti S, Riboldi G, Sava C, Spatti G, Zunino F, di Re F . 1995 Eur. J. Cancer 31A: 2248–2254
Foley J, Wysolmerski JJ, Broadus AE, Philbrick WM . 1996 Cancer Res. 56: 4056–4062
Ginsberg D, Mechta F, Yaniv M, Oren M . 1991 Proc. Natl. Acad. Sci. USA 88: 9979–9983
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC . 1994 Nucleic Acids Res. 22: 3551–3555
Iotsova V, Stehelin D . 1996 Cell Growth Differ. 7: 629–634
Jackers P, Minoletti F, Belotti D, Clausse N, Sozzi G, Sobel ME, Castronovo V . 1996 Oncogene 13: 495–503
Ko LJ, Prives C . 1996 Genes Dev. 10: 1054–1072
Landowski TH, Dratz EA, Starkey JR . 1995 Biochemistry 34: 11276–11287
Levine AJ . 1997 Cell 88: 323–331
Loging WT, Reisman D . 1999 Oncogene 18: 7608–7615
Marchuk D, Drumm M, Saulino A, Collins FS . 1991 Nucleic Acids Res. 19: 1154
Martignone S, Pellegrini R, Villa E, Tandon NN, Mastroianni A, Tagliabue E, Ménard S, Colnaghi MI . 1992 Clin. Exp. Met. 10: 379–386
McPherson LA, Weigel RJ . 1999 Nucleic Acids Res. 27: 4040–4049
Ménard S, Castronovo V, Tagliabue E, Sobel ME . 1997 J. Cell Biochem. 67: 155–165
Ménard S, Tagliabue E, Colnaghi MI . 1998 Breast Cancer Res. Treat. 52: 137–145
Nadji M, Nassiri M, Fresno M, Terzian E, Morales AR . 1999 Cancer 85: 432–436
Pal S, Datta K, Mukhopadhyay D . 2001 Cancer Res. 61: 6952–6957
Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F . 1996 Cancer Res. 56: 556–562
Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F, De Bortoli M . 2000 Oncogene 19: 280–288
Perrem K, Rayner J, Voss T, Sturzbecher H, Jackson P, Braithwaite A . 1995 Oncogene 11: 1299–1307
Raghunath P, Sidhu GS, Coon HC, Liu K, Srikantan V, Maheshwari RK . 1993 J. Biol. Regul. Homeost. Agents 7: 22–30
Rao CN, Castronovo V, Schmitt MC, Wewer UM, Claysmith AP, Liotta LA, Sobel ME . 1989 Biochemistry 28: 7476–7486
Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F . 1996 Cancer Res. 56: 689–693
Santhanam U, Ray A, Sehgal PB . 1991 Proc. Natl. Acad. Sci. USA 88: 7605–7609
Subler MA, Martin DW, Deb S . 1992 J. Virol. 66: 4757–4762
Wigler M, Pellicer A, Silverstein S, Axel R . 1978 Cell 14: 725–731
Yao KS, Godwin AK, Johnson SW, Oxols RF, O'Dwyer PJ, Hamilton TC . 1995 Cancer Res. 55: 4367–4374
Zeng YX, Somasundaram K, El-Deiry WS . 1997 Nat. Genet. 15: 78–82
Acknowledgements
We thank Dr Fabio Castiglioni for help with figures, Mrs Piera Aiello and Mrs Cristina Ghirelli for excellent technical assistance, and Mrs Laura Mameli for manuscript preparation. This work was supported by grants from AIRC. Michele Modugno was supported by a fellowship from FIRC.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Modugno, M., Tagliabue, E., Ardini, E. et al. p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene 21, 7478–7487 (2002). https://doi.org/10.1038/sj.onc.1205957
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205957
Keywords
This article is cited by
-
Knock-down of LRP/LR influences signalling pathways in late-stage colorectal carcinoma cells
BMC Cancer (2021)
-
Mutant p53 gain of function induces HER2 over-expression in cancer cells
BMC Cancer (2018)
-
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer
BMC Cancer (2011)
-
AP2α alters the transcriptional activity and stability of p53
Oncogene (2006)
-
AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
Oncogene (2006)